Start here if you're new
what it is
4D Molecular Therapeutics is trying to turn gene therapy into longer-lasting treatments for blindness and cystic fibrosis.
how it gets paid
Last year D Molecular made $37K in revenue. collaboration and license revenue was the main engine at $15K, or 40% of sales.
what just happened
Latest-quarter revenue was just $119K, while EPS fell to -$2.85, so the business still has science but not sales.
At a glance
C++ balance sheet — some cracks in the foundation
-$2.98 fy2024 eps est
$0M fy2024 rev est
n/a operating margin
1.55 beta
xvary composite: 48/100 — below average
What they do
4D Molecular Therapeutics is trying to turn gene therapy into longer-lasting treatments for blindness and cystic fibrosis.
FDMT’s edge is delivery. One eye program, 4D-150, is already in Phase 3, and one lung program, 4D-710, is the first known genetic medicine to show CFTR transgene expression in lungs after aerosol delivery, according to the company description. If you believe gene therapy wins by getting the payload to the right tissue and keeping it there, this pipeline gives you two real shots instead of a science project.
How they make money
$37K
annual revenue
collaboration and license revenue
$15K
research services revenue
$8K
grant and program revenue
$6K
manufacturing and reimbursement revenue
$5K
other revenue
$3K
The products that matter
wet AMD gene therapy
4D-150
lead asset · phase 3 focus
it matters because FDMT has just $120K of trailing revenue, so this program carries most of the current investment case.
primary catalyst
cystic fibrosis gene therapy
4D-710
pipeline option value
it adds a second shot on goal, but in a company with $120K in trailing revenue it is still secondary to 4D-150.
secondary program
engineered AAV vector platform
Vector discovery platform
theoretical until approved products
this is the broader promise behind the $425M market cap: if one vector works in the clinic, the platform can matter beyond a single asset.
platform bet
Key numbers
$2.98
FY2024 EPS est
EPS → profit per share → so what: each share is still absorbing nearly $3 of annual losses, worse than FY2023's -$2.58.
$17M
long-term debt
Long-term debt → money owed over years → so what: debt is only 4% of capital, so leverage is not the main problem. Funding and dilution are.
$37K
annual revenue
Revenue → money coming in → so what: the company is still basically pre-commercial despite a roughly $425M market cap.
1.55
beta
Beta → how violently a stock moves versus the market → so what: FDMT usually swings harder than the tape.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 2 — safer than 80% of stocks
- price stability 5 / 100
- long-term debt $17M (4% of capital)
C++ — risk rank looks solid but balance sheet grade needs watching.
Total return vs. market
Return history isn't available for FDMT right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Latest-quarter revenue was just $119K, while EPS fell to -$2.85, so the business still has science but not sales.
Revenue rose 32% vs. prior year from a tiny base, according to EDGAR. The bigger fact is the loss profile: FY2024 EPS came in at -$2.98 versus -$2.58 in FY2023 from the quarterly history provided.
$119K
revenue
$2.85
eps
n/a
n/a
the number that mattered
$119K matters because it shows the company is still early-stage. The market is funding a pipeline, not buying a proven commercial engine.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the top risk is Phase 3 failure or weak data for 4D-150 in wet AMD, because that asset is carrying most of a $425M valuation while the company reports only $120K in trailing revenue.
med
4D-150 disappoints in Phase 3
This is the main event. If the lead asset misses on efficacy, safety, or durability, the core reason investors pay up for FDMT gets hit directly.
With just $120K of trailing revenue, there is no operating business here big enough to soften a failed lead program.
med
cash runway shortens
Management says cash lasts into the latter half of 2028. Delays, larger trials, or higher development spend can move that date forward.
If the runway pulls in before the big proof points arrive, equity financing becomes much harder and much more dilutive.
med
the platform stays theoretical
The broader vector-engineering story sounds powerful, but without approved products it remains a research claim more than a commercial fact.
That leaves the stock exposed to a single-asset narrative when investors want a repeatable platform narrative.
Almost all of the current equity story sits on two things: 4D-150 working and cash lasting long enough to prove it.
source: institutional data · regulatory filings · risk analysis
Pay attention to
clinical calendar
4D-150 Phase 3 milestones
This is the event stack that matters most. Every update on timing, enrollment progress, safety, or top-line data changes the probability story.
balance sheet
cash runway versus late 2028
Management's stated runway is the clock. If that moves earlier, the stock will start pricing dilution before it prices science.
execution risk
leadership stability after the resignation
The president resigned on dec 31, 2025. Watch whether that proves isolated or becomes part of a wider execution wobble.
pipeline readthrough
4D-710 and platform credibility
A second program will not replace 4D-150, but it can tell you whether this is becoming a platform story or staying a one-asset trade.
Analyst rankings
coverage
thin
in human-speak, there is not enough broad ranked coverage in this snapshot to outsource the thesis to wall street.
volatility
1.55 beta
beta measures how much a stock tends to move versus the market. FDMT has moved more than the index.
composite view
48 / 100
the score reflects weak current fundamentals offset by optionality if the science works.
source: institutional data
Institutional activity
institutional ownership data for FDMT is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$8
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive